Business Context and Reporting Period
Prelude Therapeutics Inc. (PRLD) filed this Form 8-K on June 17, 2022, to report the results of its 2022 Annual Meeting of Stockholders held on that date. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market.
Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The filing details the successful adoption of two proposals at the Annual Meeting:
- Director Elections: Three Class II Directors were elected to three-year terms expiring at the 2025 Annual Meeting: Martin Babler, Julian Baker, and Victor Sandor, M.D.C.M.
- Auditor Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is strictly a disclosure of voting results.
Key Facts for Investor Verification
- Voting Results: All three director nominees received significant support, with "For" votes ranging from approximately 25.6 million to 27.0 million shares.
- Broker Non-Votes: There were 1,215,046 broker non-votes recorded for each director nominee.
- Auditor Support: The ratification of Ernst & Young LLP received 28,293,151 votes "For," with only 5,385 votes "Against" and 5,495 abstentions.
- Term Expiration: The newly elected directors will serve until the 2025 Annual Meeting.